EcoR1 Capital, LLC (NODELMAN OLEG) purchased $17.2M of ANAB (indirect holdings)

EcoR1 Capital, LLC purchased 374,580 indirectly-held shares of ANAPTYSBIO, INC (ANAB) at an average of $45.98 ($45.66–$46.54, $17.22M total) across 3 trades over 2026-11-16 to 2026-11-18. Filed jointly with NODELMAN OLEG (Director).

Original reporting
SEC EDGAR · EcoR1 Capital, LLC, NODELMAN OLEG
Published Nov 18, 2026, 11:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 11:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ANAB
Neutral
medium confidence
Mentioned
$ANAB
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANABNeutralLow
01

Why it matters

ANAB receives a disclosed increase in holdings through open-market purchases totaling $17.2M, but the filing does not include new business developments or forward-looking guidance.

02

Market read

Traders may treat the disclosure as a mild sentiment input, but it is unlikely to drive a durable repricing without corroborating fundamental catalysts.

03

What to watch

The transaction is indirect and lacks a stated 10b5-1 plan; without context on prior holdings or intent, the signal strength is uncertain.

Relevance 8/10Novelty 5/10Timing: Form 4 filed 2026-11-18, covering purchases from 2026-11-16 to 2026-11-18.

Background

The article is an SEC Form 4 insider transaction disclosure for ANAPTYSBIO, INC, reported by EcoR1 Capital, LLC (director, 10% owner) with joint filer NODELMAN OLEG.

Company-level read

Ticker impact

$ANABNeutralMedium confidence
Context

EcoR1 Capital, LLC reported an open-market purchase totaling about $17.2M in ANAB shares via a Form 4 filed 2026-11-18.

Expected impact

Likely limited near-term impact, with any reaction more sentiment-driven than thesis-changing.

Evidence & confidence

This is an SEC Form 4 insider transaction (indirect holdings) with no stated 10b5-1 plan and no accompanying company-specific operational news.

Market effects

Minimal, as the disclosure is company-specific insider buying without sector-wide regulatory or competitive implications.

None indicated.

None indicated.

Counterpoint

Insider-linked buying can be routine portfolio rebalancing or indirect holdings activity, so it may not reflect new positive fundamentals.

Key entities

  • ANAPTYSBIO, INC

    Company whose shares were purchased, disclosed via SEC Form 4.

  • EcoR1 Capital, LLC

    Reported the open-market purchase totaling about $17.2M in ANAB shares.

  • NODELMAN OLEG

    Joint filer and director, 10% owner role listed on the Form 4.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ANABHighAI 8/10

ANAPTYSBIO, INC (ANAB): Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update

ANAPTYSBIO, INC (ANAB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update • Jemperli global net sales of $1.0 billion (£753 million) for the nine months ended September 30, 2026, representing 29% year-over-year growth • Jemperli approved in the U.S. as

$ANABHighAI 9/10

AnaptysBio, Inc. (ANAB) Gets FDA OK for Jemperli in MSI-H/dMMR Rectal Cancer

AnaptysBio (ANAB) announced FDA approval for GSK's Jemperli as the first immunotherapy for adults with stage II-III MSI-H/dMMR locally advanced rectal cancer. The approval, based on AZUR-1 data, shows 68% of participants had no detectable cancer after one year, with no recurrences reported after 2+ years of follow-up. GSK will present full data at ESMO Congress 2026.

$ANABHighAI 9/10

AnaptysBio (ANAB) Shares Rise After GSK's FDA Label Expansion fo

AnaptysBio (ANAB) shares rose after partner GSK received FDA approval for an expanded label of anti-PD-1 therapy Jemperli. The approval allows marketing for a new cancer indication, accelerating regulatory action. ANAB's P/E ratio is 7.64x, below its 5-year median. Insider activity shows net selling. ANAB's GF Score is 43/100, reflecting mixed fundamentals.

$ANABHighAI 8/10

AnaptysBio gains as GSK granted FDA label expansion for Jemperli

AnaptysBio (ANAB) rose after partner GSK (GSK) received FDA approval to expand Jemperli's label for treating certain rectal cancers. The drug is now approved for adults with stage II/III MSI-H/dMMR locally advanced rectal cancer, a subset of 5%-10% of rectal cancers. The approval came earlier than the expected February 2027 date.